Effect of Tricuspid Valve Repair or Replacement on Survival in Patients With Isolated Severe Tricuspid Regurgitation

• Published in: The American journal of cardiology 2022-01, Vol.162, p.163-169
• Main Authors: Wang, Tom Kai Ming, Mentias, Amgad, Akyuz, Kevser, Kirincich, Jason, Crane, Alejandro Duran, Popovic, Zoran B., Xu, Bo, Gillinov, Alan Marc, Pettersson, Gosta B., Griffin, Brian P., Desai, Milind Y.
• Format: Article
• Language: English
• Subjects: Age; Aged; Aged, 80 and over; Cardiovascular disease; Cohort Studies; Confidence intervals; Congestive heart failure; Echocardiography; Endocarditis; Etiology; Female; Heart attacks; Heart failure; Heart Valve Prosthesis Implantation; Hospital Mortality; Hospitalization; Humans; Laboratories; Male; Medical prognosis; Middle Aged; Morbidity; Mortality; Patients; Regression analysis; Regurgitation; Sensitivity analysis; Severity of Illness Index; Statistical analysis; Stroke; Subgroups; Surgery; Survival; Survival Rate; Time Factors; Treatment Outcome; Tricuspid valve; Tricuspid Valve Insufficiency - mortality; Tricuspid Valve Insufficiency - surgery
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2021.08.069

Controversies remain in the management strategy for isolated tricuspid regurgitation (TR) because of adverse prognosis and uncertainties regarding the benefits of tricuspid valve surgery. We compared the characteristics and outcomes of a large cohort of patients with isolated TR, based on downstream tricuspid valve surgery versus medical management. Consecutive patients with isolated TR graded at least moderate-to-severe by echocardiography identified between January 2004 and December 2018 (n = 9,031, age 70 ± 15 years, 60% women) were retrospectively studied. The primary end point was time to all-cause mortality during follow-up. Outcomes were compared by management strategy using unadjusted and adjusted survival and multivariable regression analyses. Tricuspid valve surgery was performed in 632 of 9,031 of the cohort (7%), including 514 valve repairs and 118 valve replacements, with in-hospital mortality in 19 patients (2.9%). Overall, there were 3,985 all-cause deaths (44%) over mean follow-up of 2.6 ± 3.3 years. Tricuspid valve surgery was independently associated with lower mortality rate during follow-up, with hazard ratios (HRs) of 0.53 (95% confidence interval [CI] 0.45 to 0.64), and the association persisted in both primary and secondary TR subgroups. Tricuspid valve surgery also had a significantly higher rate of infective endocarditis and heart failure hospitalizations rates during follow-up, at HRs of 5.55 (95% CI 4.00 to 7.71) and 1.29 (95% CI 1.16 to 1.43), respectively. In conclusion, tricuspid valve surgery is rarely performed in isolated TR, but it is independently associated with greater survival for the overall cohort and both primary and secondary etiology subgroups. Increasing the utilization of this surgery at specialized centers is encouraged to try to improve the clinical outcomes for this challenging clinical entity.